FDA approves AstraZeneca's Imfinzi with enfortumab vedotin for bladder cancerNov 16Regulatory decisionAstraZenecadurvalumab
FDA approves durvalumab plus enfortumab vedotin for muscle invasive bladder cancerNov 13Regulatory decisionAstraZenecadurvalumabUpdated
Eikon reports Q3 2026 results, ESMO oncology data and new prostate cancer INDNov 12Quarterly updateAkari Therapeutics PlcAtrium Therapeutics
FDA accelerated approval covers Padcev plus Keytruda in urothelial carcinomaNov 9Regulatory decisionenfortumab vedotinMerck & Co., Inc.
Bicara reaches substantial enrollment in HPV-negative head and neck cancer trialNov 9Quarterly updateArriVent BioPharma, Inc.Bicara Therapeutics
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Merck posts Q3 2026 results with oncology approvals and new sac-TMT regulatory filingOct 29Quarterly updateGilead SciencesMerck & Co., Inc.
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
Summit Therapeutics registers Phase 2/3 HARMONi-GU1 trial in urothelial carcinomaSep 11Trial updateivonescimabSummit Therapeutics
Generate Biomedicines reports Q2 2026 results, advances asthma and oncology pipelineAug 6Quarterly updateGenerate Biomedicines
Summit Therapeutics starts Phase II/III bladder cancer trial for ivonescimabAug 5Clinical readoutivonescimabSummit Therapeutics
Merck posts Q2 loss on Terns charge, raises full-year sales outlookAug 4Quarterly updateMerck & Co., Inc.
Innate Pharma completes enrollment in Phase 1 study of Nectin-4 ADC IPH4502Jul 21Trial updateInnate PharmaIPH4502